Hot topics in pharmacology

Recent publications of interest recommended by NC-IUPHAR

2018: Jan | Feb | Mar | Apr

April 2018

Structure of the insulin receptor-insulin complex by single-particle cryo-EM analysis
(1) Scapin G et al. (2018). Structure of the insulin receptor-insulin complex by single-particle cryo-EM analysis. Nature, 556(7699):122-125. doi: 10.1038/nature26153. [PMID:29512653]


Quantitative Prediction of Rate Constants for Aqueous Racemization To Avoid Pointless Stereoselective Syntheses
(1) Ballard A et al. (2018). Quantitative Prediction of Rate Constants for Aqueous Racemization To Avoid Pointless Stereoselective Syntheses. Angew Chem Int Ed Engl., 57(4):982-985. doi: 10.1002/anie.201709163. [PMID:29072355]


Searching and Extracting Data from the EMBL-EBI Complex Portal
(1) Meldal BHM, Orchard S. (2018). Searching and Extracting Data from the EMBL-EBI Complex Portal. Methods Mol Biol., 1764:377-390. doi: 10.1007/978-1-4939-7759-8_24. [PMID:29605928]


Accurate functional classification of thousands of BRCA1 variants with saturation genome editing
(1) Findlay GM et al. (2018). Accurate functional classification of thousands of BRCA1 variants with saturation genome editing. BioRxiv, doi: 10.1101/294520. [Epub ahead of print] [Abstract]


Opportunities and obstacles for deep learning in biology and medicine
(1) Ching T et al. (2018). Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface., 15(141). pii: 20170387. doi: 10.1098/rsif.2017.0387. [PMID:29618526]


The Immune Landscape of Cancer
(1) Thorsson V et al. (2018). The Immune Landscape of Cancer. Immunity, doi: 10.1016/j.immuni.2018.03.023. [Epub ahead of print] [Full text]


Disease-Causing Mutations in the G Protein Gαs Subvert the Roles of GDP and GTP
(1) Hu Q, Shokat KM. (2018). Disease-Causing Mutations in the G Protein Gαs Subvert the Roles of GDP and GTP. Cell, doi: 10.1016/j.cell.2018.03.018. [Epub ahead of print] [Full text]


Identification of Misclassified ClinVar Variants via Disease Population Prevalence
(1) Shah N et al. (2018). Identification of Misclassified ClinVar Variants via Disease Population Prevalence. Am J Hum Genet., 102(4):609-619. doi: 10.1016/j.ajhg.2018.02.019. [PMID:29625023]


Chemical Diversity in the G Protein-Coupled Receptor Superfamily
(1) Vass M et al. (2018). Chemical Diversity in the G Protein-Coupled Receptor Superfamily. Trends Pharmacol Sci., pii: S0165-6147(18)30035-X. doi: 10.1016/j.tips.2018.02.004. [Epub ahead of print] [PMID:29576399]


Synthesis and Characterization of a Bidirectional Photoswitchable Antagonist Toolbox for Real-Time GPCR Photopharmacology
(1) Hauwert NJ et al. (2018). Synthesis and Characterization of a Bidirectional Photoswitchable Antagonist Toolbox for Real-Time GPCR Photopharmacology. J Am Chem Soc., 140(12):4232-4243. doi: 10.1021/jacs.7b11422. [PMID:29470065]


Cross-disorder analysis of schizophrenia and 19 immune diseases reveals genetic correlation
(1) Pouget JG, et al. (2018). Cross-disorder analysis of schizophrenia and 19 immune diseases reveals genetic correlation. BioRxiv, doi: 10.1101/068684. [Epub ahead of print] [Abstract]


Planning chemical syntheses with deep neural networks and symbolic AI
(1) Segler MHS et al. (2018). Planning chemical syntheses with deep neural networks and symbolic AI. Nature, 555(7698):604-610. doi: 10.1038/nature25978. [PMID:29595767]


Biased signalling: from simple switches to allosteric microprocessors
(1) Smith JS et al. (2018). Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov, 17(4):243-260. doi: 10.1038/nrd.2017.229. [PMID:29302067]


ImmPort, toward repurposing of open access immunological assay data for translational and clinical research
(1) Bhattacharya S et al. (2018). ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data, 5:180015. doi: 10.1038/sdata.2018.15. [PMID:29485622]


Organic synthesis provides opportunities to transform drug discovery
(1) Blakemore DC et al. (2018). Organic synthesis provides opportunities to transform drug discovery. Nat Chem, 10(4):383-394. doi: 10.1038/s41557-018-0021-z. [PMID:29568051]


March 2018

3D structures of the closed acid-sensing ion channel (ASIC) shed light on the activation mechanism of these neuronal ion channels

Comments by Stephan Kellenberger, Université de Lausanne, Switzerland

ASICs are potential drug targets of interest. Their activation mechanism has however remained elusive. ASICs are neuronal, proton-gated, sodium-permeable channels that are expressed in the central and peripheral nervous system of vertebrates. They form a subfamily of the Epithelial Na channel / degenerin channel family, and contribute to pain sensation, fear, learning, and neurodegeneration after ischemic stroke. Depending on the extracellular pH, they exist in either one of three functional states: closed (resting), open and desensitized. While ASICs are at physiological pH 7.4 in the closed state, they open briefly upon extracellular acidification, before entering the non-conducting desensitized state. Crystal structures of the chicken ASIC1 channel in the desensitized and the open state were published several years ago. This structural information allowed, together with observations from functional studies, an understanding of the transitions between the open and the desensitized state. In contrast, the absence of structural information on the closed conformation of ASICs precluded so far a molecular understanding of their activation mechanism.

The Gouaux laboratory has now published structures of the homotrimeric chicken ASIC1 obtained at high pH by X-ray crystallography (2.95 Å resolution) and by single particle cryo-electron microscopy (3.7 Å) (1). Read the full article on our blog

(1) Yoder N et al. (2018). Gating mechanisms of acid-sensing ion channels. Nature, 555(7696):397-401. doi: 10.1038/nature25782. [PMID:29513651]


Extensive impact of non-antibiotic drugs on human gut bacteria
(1) Maier L, et al. (2018). Extensive impact of non-antibiotic drugs on human gut bacteria. Nature, doi:10.1038/nature25979. [Epub ahead of print] [Full text]


A Machine Learning Approach Predicts Tissue-Specific Drug Adverse Events
(1) Madhukar NS, et al. (2018). A Machine Learning Approach Predicts Tissue-Specific Drug Adverse Events. BioRxiv, doi: 10.1101/288332. [Epub ahead of print] [Abstract]


Ranking Enzyme Structures in the PDB by Bound Ligand Similarity to Biological Substrates
(1) Tyzack JD et al. (2018). Ranking Enzyme Structures in the PDB by Bound Ligand Similarity to Biological Substrates. Structure, pii: S0969-2126(18)30049-2. doi: 10.1016/j.str.2018.02.009. [Epub ahead of print] [PMID:29551288]


Structural insights into the voltage and phospholipid activation of the mammalian TPC1 channel
(1) She J et al. (2018). Structural insights into the voltage and phospholipid activation of the mammalian TPC1 channel. Nature, doi: 10.1038/nature26139. [Epub ahead of print] [PMID:29562233]


Conflicting evidence for the role of JNK as a target in breast cancer cell proliferation: Comparisons between pharmacological inhibition and selective shRNA knockdown approaches
(1) Wood RA et al. (2018). Conflicting evidence for the role of JNK as a target in breast cancer cell proliferation: Comparisons between pharmacological inhibition and selective shRNA knockdown approaches. Pharmacol Res Perspect., 6(1). doi: 10.1002/prp2.376. [PMID:29417765]


Closely related, yet unique: Distinct homo- and heterodimerization patterns of G protein coupled chemokine receptors and their fine-tuning by cholesterol
(1) Gahbauer S et al. (2018). Closely related, yet unique: Distinct homo- and heterodimerization patterns of G protein coupled chemokine receptors and their fine-tuning by cholesterol. PLoS Comput Biol., 14(3):e1006062. doi: 10.1371/journal.pcbi.1006062. [PMID:29529028]


Engineered mini G proteins provide a useful tool for studying the activation of GPCRs in living cells

Comments by Shane C. Wright and Gunnar Schulte, Karolinska Institute

In order to stabilize the GPCR-G protein complex, an agonist must be bound to the receptor and the alpha subunit of the heterotrimer must be in a nucleotide-free state. Ground-breaking work by expert crystallographers made use of so-called mini G (mG) proteins to stabilize the active conformation of the adenosine A2A receptor in the presence of agonist and guanine nucleotides, but in the absence of Gβγ [1]. These engineered G proteins behave in a way that mimics the nucleotide-free state despite being bound to GDP; thus, they can be seen as conformational sensors of the active receptor state. This work paved the way for another study recently published in the Journal of Biological Chemistry led by Nevin A. Lambert that looked to build on this minimalistic approach to see if representative mG proteins from the four subclasses (Gs, Gi/o, Gq/11 and G12/13) could 1) detect active GPCRs and 2) retain coupling specificity [2]. Read the full article on our blog

(1) Carpenter B et al. (2016) Structure of the adenosine A(2A) receptor bound to an engineered G protein. Nature, 536 (7614): 104-107. [PMID:27462812]
(2) Wan Q et al. (2018) Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. J Biol Chem. pii: jbc.RA118.001975. doi: 10.1074/jbc.RA118.001975. [Epub ahead of print] [PMID:29523687]


Functionally distinct and selectively phosphorylated GPCR subpopulations co-exist in a single cell
(1) Shen A et al. (2018). Functionally distinct and selectively phosphorylated GPCR subpopulations co-exist in a single cell. Nat Commun., 9(1):1050. doi: 10.1038/s41467-018-03459-7. [PMID:29535304]


Heterologous Expression, Biosynthetic Studies, and Ecological Function of the Selective Gq-Signaling Inhibitor FR900359
(1) Crüsemann M et al. (2018). Heterologous Expression, Biosynthetic Studies, and Ecological Function of the Selective Gq-Signaling Inhibitor FR900359. Angew Chem Int Ed Engl., 57(3):836-840. doi: 10.1002/anie.201707996. [PMID:29194875]


A comprehensive and quantitative comparison of text-mining in 15 million full-text articles versus their corresponding abstracts
(1) Westergaard D et al. (2018). A comprehensive and quantitative comparison of text-mining in 15 million full-text articles versus their corresponding abstracts. PLoS Comput Biol., 4(2):e1005962. doi: 10.1371/journal.pcbi.1005962. [PMID:29447159]


Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults
(1) Perkins BA et al. (2018). Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults. Proc Natl Acad Sci U S A., pii: 201706096. doi: 10.1073/pnas.1706096114. [Epub ahead of print] [PMID:29555771]


Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist
(1) Yin W et al. (2018). Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist. Cell Discovery, 4. doi:10.1038/s41421-018-0009-2. [Epub ahead of print] [Full text]


Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next Level
(1) Wolle P et al. (2018). Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next Level. ACS Chem Biol., 13(3):496-499. doi: 10.1021/acschembio.8b00153. [PMID:29544257]


Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design
(1) Basith S et al. (2018). Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design. Frontiers in Pharmacology, doi:10.3389/fphar.2018.00128. [Epub ahead of print] [Full text]


WhichP450: a multi-class categorical model to predict the major metabolising CYP450 isoform for a compound
(1) Hunt PA et al. (2018). WhichP450: a multi-class categorical model to predict the major metabolising CYP450 isoform for a compound. J Comput Aided Mol Des., doi: 10.1007/s10822-018-0107-0. [Epub ahead of print] [PMID:29464466]


Validation of ligands in macromolecular structures determined by X-ray crystallography
(1) Smart OS et al. (2018). Validation of ligands in macromolecular structures determined by X-ray crystallography. Acta Crystallogr D Struct Biol., 74(Pt 3):228-236. doi: 10.1107/S2059798318002541. [PMID:29533230]


Translational Bioinformatics year in review 2018
(1) Altman R. (2018). [Translational Bioinformatics year in review 2018]


Pharma R&D Annual Review 2018
(1) Lloyd I. (2018). [Pharma R&D Annual Review 2018]


Small Molecule Interactome Mapping by Photoaffinity Labeling Reveals Binding Site Hotspots for the NSAIDs
(1) Gao J et al. (2018). Small Molecule Interactome Mapping by Photoaffinity Labeling Reveals Binding Site Hotspots for the NSAIDs. J Am Chem Soc., doi: 10.1021/jacs.7b11639. [Epub ahead of print] [PMID:29543447]


Kinase inhibitors: the road ahead
(1) Ferguson FM, Gray NS. (2018). Kinase inhibitors: the road ahead. Nat Rev Drug Discov., doi: 10.1038/nrd.2018.21. [Epub ahead of print] [PMID:29545548]


STRENDA DB: enabling the validation and sharing of enzyme kinetics data
(1) Swainston N et al. (2018). STRENDA DB: enabling the validation and sharing of enzyme kinetics data. FEBS J., doi: 10.1111/febs.14427. [Epub ahead of print] [PMID:29498804]


Genetic risk for Alzheimer's disease is concentrated in specific macrophage and microglial transcriptional networks
(1) Tansey KE et al. (2018). Genetic risk for Alzheimer's disease is concentrated in specific macrophage and microglial transcriptional networks. Genome Med., 10(1):14. doi: 10.1186/s13073-018-0523-8. [PMID:29482603]


Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions
(1) Lu S, Zhang J. (2018). Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions. J Med Chem, doi: 10.1021/acs.jmedchem.7b01844. [Epub ahead of print] [PMID:29457894]


Unexplored therapeutic opportunities in the human genome

Comments by Chris Southan, IUPHAR/BPS Guide to PHARMACOLOGY, @cdsouthan

Contemporary drug discovery is dominated by two related themes. The first of these is target validation upon which the sustainability of pharmaceutical R&D (in both the commercial and academic sectors) crucially depends. The second is the size of the pool of human proteins that are/could become tractable to being progressed towards clinical efficacy as their final validation step (otherwise known as the druggable proteome). This usefully detailed review, by a large team of authors, touches on both themes but with a focus on how the community might increase the target pool by data-driven knowledge expansion for hitherto less well characterised proteins [1]. Read the full article on our blog

(1) Oprea TI et al. (2018). Unexplored therapeutic opportunities in the human genome. Nat Rev Drug Discov. doi: 10.1038/nrd.2018.14 [Epub ahead of print] [PMID:29472638]


Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register
(1) Fleminger J, Goldacre B. (2018). Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register. PLoS One, 13(3):e0193088. doi: 10.1371/journal.pone.0193088. [PMID:29513684]


An Augmented Pocketome: Detection and Analysis of Small-Molecule Binding Pockets in Proteins of Known 3D Structure
(1) Bhagavat R et al. (2018). An Augmented Pocketome: Detection and Analysis of Small-Molecule Binding Pockets in Proteins of Known 3D Structure. Structure, 26(3):499-512.e2. doi: 10.1016/j.str.2018.02.001. [PMID:29514079]


Cryo-EM and X-ray structures of TRPV4 reveal insight into ion permeation and gating mechanisms
(1) Deng Z et al. (2018). Cryo-EM and X-ray structures of TRPV4 reveal insight into ion permeation and gating mechanisms. Nat Struct Mol Biol., 25(3):252-260. doi: 10.1038/s41594-018-0037-5. [PMID:29483651]


The role of gut microbiome and associated metabolome in the regulation of neuroinflammation in multiple sclerosis and its implications in attenuating chronic inflammation in other inflammatory and autoimmune disorders
(1) Dopkins N, Nagarkatti PS, Nagarkatti M. (2018). The role of gut microbiome and associated metabolome in the regulation of neuroinflammation in multiple sclerosis and its implications in attenuating chronic inflammation in other inflammatory and autoimmune disorders. Immunology, doi: 10.1111/imm.12903. [Epub ahead of print] [PMID:29392733]


The rise of deep learning in drug discovery
(1) Chen H et al. (2018). The rise of deep learning in drug discovery. Drug Discov Today, pii: S1359-6446(17)30359-8. doi: 10.1016/j.drudis.2018.01.039. [Epub ahead of print] [PMID:29366762]


Big Data in Drug Discovery
(1) Brown N et al. (2018). Big Data in Drug Discovery. Progress in Medicinal Chemistry, doi:10.1016/bs.pmch.2017.12.003. [Epub ahead of print] [Abstract]


February 2018

The G Protein-Coupled Receptors deorphanization landscape

Comments by Julien Hanson, University of Liege

This paper (1) sheds some light on the current state of the field and the phenomenon of reduced discoveries in the orphan landscape. Although it is true that fewer deorphanizations have been reported recently compared to the 1990-2000 period, the authors propose that the rate has reached a "steady-state" stage. Nevertheless, with more than 100 remaining orphans, the daunting task of full deorphanization that lies ahead will require creative approaches both at the technical and conceptual level. Read the full article on our blog

(1) Laschet C, Dupuis N, Hanson J. (2018). The G Protein-Coupled Receptors deorphanization landscape. Biochem Pharmacol., pii: S0006-2952(18)30073-X. doi: 10.1016/j.bcp.2018.02.016. [Epub ahead of print] [PMID:29454621]


Integrative omics for health and disease
(1) Karczewski KJ and Snyder MP. (2018). Integrative omics for health and disease. Nature Reviews Genetics, doi:10.1038/nrg.2018.4. [Epub ahead of print] [Full text]


Selective Photoaffinity Probe That Enables Assessment of Cannabinoid CB2 Receptor Expression and Ligand Engagement in Human Cells
(1) Soethoudt M et al. (2018). Selective Photoaffinity Probe That Enables Assessment of Cannabinoid CB2 Receptor Expression and Ligand Engagement in Human Cells. J Am Chem Soc., doi: 10.1021/jacs.7b11281. [Epub ahead of print] [PMID:29420021]


Caveat usor: assessing differences between major chemistry databases
(1) Southan C. (2018). Caveat usor: assessing differences between major chemistry databases. ChemMedChem., doi: 10.1002/cmdc.201700724. [Epub ahead of print] [PMID:29451740]


£54 million funding to transform UK health through data science
Health Data Research UK is awarding £30 million funding to six sites across the UK to address challenging healthcare issues through use of data science. Each site has world-class expertise; a track record in using health data to derive new knowledge, scientific discovery and insight; and works in close partnership with NHS bodies and the public to translate research findings into benefits for patients and populations. [Read more at Health Data Research UK]


The 100,000 Genomes Project
The project will sequence 100,000 genomes from around 70,000 people. Participants are NHS patients with a rare disease, plus their families, and patients with cancer. [Read more at Genomics England]


BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology
(1) Peters F et al. (2018). BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology. Acta Neuropathol., doi: 10.1007/s00401-017-1804-9. [Epub ahead of print] [PMID:29327084]


5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology
(1) Peng Y et al. (2018). 5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. Cell, 172(4):719-730.e14. doi: 10.1016/j.cell.2018.01.001. [PMID:29398112]


Deubiquitylating enzymes and drug discovery: emerging opportunities
(1) Harrigan JA et al. (2018). Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov., 17(1):57-78. doi: 10.1038/nrd.2017.152. [PMID:28959952]


January 2018

Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone
(1) Wang S et al. (2018). Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature, doi:10.1038/nature25758. [Epub ahead of print]. [Abstract]


The Enduring Legacy of 250 Years of Pharmacology in Edinburgh
(1) Kelly JS, Mackay AVP. (2018). The Enduring Legacy of 250 Years of Pharmacology in Edinburgh. Annu Rev Pharmacol Toxicol., 58:293-307. doi: 10.1146/annurev-pharmtox-010617-052901 [PMID:28934562]


A Serendipitous Scientist
(1) Lefkowitz RJ. (2018). A Serendipitous Scientist. Annu Rev Pharmacol Toxicol., 58:17-32. doi: 10.1146/annurev-pharmtox-010617-053149. [PMID:28715979]


Pharmacogenomics of GPCR Drug Targets

Comments by Alexander Hauser, University of Copenhagen and GPCRdb

A collaboration between the MRC Laboratory of Molecular Biology, Cambridge (UK), the Scripps Research Institute in Florida and the Department of Drug Design and Pharmacology, University of Copenhagen (home of the GPCRdb team) has now published a new detailed study on the effects of genetic variation in G protein-coupled receptors on responses to FDA-approved drugs [1]. The authors address the following main questions: How variable are GPCR drug targets in the human population? Are individuals with variant receptors likely to respond differently to drugs? What is the estimated economic burden associated with variation in GPCR drug targets? Read the full article on our blog

(1) Hauser AS et al. (2017). Pharmacogenomics of GPCR Drug Targets. Cell, 172(1-2):41-54.e19. doi:10.1016/j.cell.2017.11.033. [PMID:29249361]


Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor
(1) Che T et al. (2018). Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. Drug Discov Today, 172(1-2):55-67.e15. doi: 10.1016/j.cell.2017.12.011. [PMID:29307491]


Drug target residence time: a misleading concept
(1) Folmer RHA. (2017). Drug target residence time: a misleading concept. Drug Discov Today, S1359-6446(17)30241-6. doi: 10.1016/j.drudis.2017.07.016. [PMID:28782685]


GPCRs as targets for approved drugs: How many targets and how many drugs?
(1) Sriram K & Insel PA. (2018). GPCRs as targets for approved drugs: How many targets and how many drugs? Mol Pharmacol., doi: 10.1124/mol.117.111062. [Epub ahead of print]. [PMID:29298813]


International Union of Basic and Clinical Pharmacology CIII
(1) Kennedy AJ & Davenport AP. (2018). International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function. Pharmacol Rev., 70(1):174-196. doi: 10.1124/pr.116.013177. [PMID:29279348]


Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727
(1) Roberston N et al. (2018). Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727. Nature, 553(7686):111-114 doi: 10.1038/nature25025. [PMID:29300009]


Structure of the glucagon receptor in complex with a glucagon analogue
(1) Zhang H et al. (2018). Structure of the glucagon receptor in complex with a glucagon analogue. Nature, 553(7686):106-110. doi: 10.1038/nature25153. [PMID:29300013]


Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor
(1) Eddy MT et al. (2017). Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor. Cell Chem Biol., 172(1-2):68-80.e12. doi: 10.1016/j.cell.2017.12.004. [PMID:29290469]


Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions
(1) Tang J et al. (2017). Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. Cell Chem Biol., S2451-9456(17)30426-9. doi: 10.1016/j.chembiol.2017.11.009. [PMID:29276046]


A dynamic map for learning, communicating, navigating and improving therapeutic development
(1) Wagner J et al. (2017). A dynamic map for learning, communicating, navigating and improving therapeutic development. Nat Rev Drug Discov., [EPub ahead of print]. doi: 10.1038/nrd.2017.217. [PMID:29269942]


Residue-Specific Peptide Modification: A Chemist's Guide
(1) deGruyter JN et al. (2017). Residue-Specific Peptide Modification: A Chemist's Guide. Biochemistry., 56(30):3863-3873. doi: 10.1021/acs.biochem.7b00536. [PMID:28653834]


Phenome-wide association studies (PheWAS) across large "real-world data" population cohorts support drug target validation
(1) Diogo D et al. (2017). Phenome-wide association studies (PheWAS) across large "real-world data" population cohorts support drug target validation BioRxiv., doi: https://doi.org/10.1101/218875. [Full text]


The spectrum of T cell metabolism in health and disease.
(1) Bantug GR et al. (2017). The spectrum of T cell metabolism in health and disease. Nat Rev Immunol., 18(1):19-34. doi: 10.1038/nri.2017.99. [PMID:28944771]


Genetic variation in human drug-related genes
(1) Schärfe CPI et al. (2017). Genetic variation in human drug-related genes. Genome Med., 9(1):117. doi: 10.1186/s13073-017-0502-5. [PMID:29273096]


Complex Portal - A Unifying Protein Complex Database
(1) Meldal, B et al. (2017). Complex Portal - A Unifying Protein Complex Database. Genomics and Computational Biology, [S.l.], v. 4, n. 1, p. e100052, dec. 2017. ISSN 2365-7154. [Full text]


Archive of previous years